- Home
- TMS vs TBPH Comparison
TMS vs TBPH Comparison
Compare TMS & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TMS | TBPH |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.1M | 908.9M |
| IPO Year | 2025 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TMS | TBPH |
|---|---|---|
| Price | $5.74 | $16.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | 66.1K | ★ 906.3K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.48 | $10.82 |
| 52 Week High | $10.10 | $21.03 |
Technical Indicators
Market Signals| Indicator | TMS | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 23.49 | 50.57 |
| Support Level | N/A | $16.17 |
| Resistance Level | $8.42 | $17.21 |
| Average True Range (ATR) | 0.66 | 0.11 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 5.05 | 12.50 |
Price Performance
Historical ComparisonAbout TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.